sulfochloranthine: combination of dichlorodimethylhydantoin, dimethylhydantoin, sodium polyphosphate, sulfanol [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 8360 |
| CHEMBL ID | 1899986 |
| SCHEMBL ID | 123299 |
| MeSH ID | M0106418 |
| Synonym |
|---|
| AC-1604 |
| c5h6cl2n2o2 |
| nsc-38630 |
| nsc38630 |
| nsc-33307 |
| hydantoin,3-dichloro-5,5-dimethyl- |
| daktin |
| 2, 1,3-dichloro-5,5-dimethyl- |
| dactin |
| nci-c03054 |
| dichlorantin |
| hydan |
| dantoin |
| halane |
| wln: t5nvnv ehj ag cg e1 e1 |
| hydantoin, dichlorodimethyl- |
| 1,5-dimethyl hydantoin |
| omchlor |
| nsc33307 |
| 118-52-5 |
| 1,5-dimethylhydantoin |
| 1,3-dichloro-5,5-dimethyl-imidazolidine-2,4-dione |
| hydantoin, 1,3-dichloro-5,5-dimethyl- (8ci) |
| DDH , |
| 1,3-dichloro-5,5-dimethylhydantoin, available chlorine 68 % |
| NCGC00164351-01 |
| 1,3-dichloro-5,5-dimethyl-2,4-imidazolidinedione |
| hydantoin, 1,3-dichloro-5,5-dimethyl- |
| caswell no. 306 |
| ai3-23669 |
| 1,3-dwuchloro-5,5-dwumetylohydantoina [polish] |
| dwuchlorantyny [polish] |
| epa pesticide chemical code 028501 |
| nsc 33307 |
| 1,3-dichloro-5,5-dimethyl hydantoin |
| nsc 38630 |
| sulfochloranthine |
| ccris 5900 |
| 1,3-dichloro-5,5'-methylhydantoin |
| hydan (antiseptic) |
| brn 0146013 |
| hsdb 4373 |
| einecs 204-258-7 |
| 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione |
| 2,4-imidazolidinedione, 1,3-dichloro-5,5-dimethyl- |
| 1,3-dichloro-5,5-dimethylhydantoin |
| D1783 |
| STK802311 |
| AKOS000120004 |
| NCGC00164351-03 |
| NCGC00164351-02 |
| dwuchlorantyny |
| 1,3-dwuchloro-5,5-dwumetylohydantoina |
| unii-70h8b2wwtu |
| sulfochlorantine |
| 5-24-05-00373 (beilstein handbook reference) |
| 70h8b2wwtu , |
| tox21_202384 |
| tox21_300184 |
| dtxcid604985 |
| NCGC00254084-01 |
| NCGC00259933-01 |
| dtxsid4024985 , |
| cas-118-52-5 |
| BBL011089 |
| FT-0606647 |
| dichloro-5,5-dimethylhydantoin, 1,3- |
| 1,3-dichloro-5,5-dimethylhydantoin [hsdb] |
| j5.299j , |
| 1,3-dichloro-5,5-dimethylhydantoin [mi] |
| 1 ,3-dichloro-5,5-dimethylhydantoin |
| 1,3-dichloro-5,5-dimethyl-hydantoin |
| dichlorodimethylhydantoin |
| SCHEMBL123299 |
| dantochlor rw |
| dcdmh |
| 1,3-dichloro-5,5-dimethylhydantoine |
| CHEMBL1899986 |
| W-108540 |
| mfcd00003190 |
| F0001-0296 |
| chlorantine |
| CS-W018514 |
| VS-02831 |
| Q20963665 |
| chlorosulfonicacid |
| EN300-19870 |
| D77848 |
| 1,3-dichloro-dimethylhydantoin |
| 2,4-imidazolidinedione, 1,3-dichloro-5,5-dimethyl-; n,n'-dichlorodimethylhydantoin; 1,3-dichloro-5,5-dimethylhydantoin; 1,3-dichloro-5,5-dimethyl-imidazolidine-2,4-dione |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Animals were dosed topically with 'test article'--neat HD, 10% agent/chloroform solutions or product solutions (waste-streams) from neutralized CAIS--and evaluated for skin-damaging effects (gross and microscopic)." | ( Evaluation of neutralized chemical agent identification sets (CAIS) for skin injury with an overview of the vesicant potential of agent degradation products. Hayes, TL; MacIver, B; Menton, RG; Miller, TL; Olajos, EJ; Olson, CT; Rosso, T; Salem, H; Singer, AW, ) | 0.13 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 61.7353 | 0.0002 | 21.2231 | 8,912.5098 | AID743036 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 0.0028 | 0.0002 | 14.3764 | 60.0339 | AID588532 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 6.9626 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 27.9005 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1259401 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 25.3554 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743077; AID743079 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 68.6594 | 0.0007 | 23.0674 | 1,258.9301 | AID743085 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 1.3699 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (34.80) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||